Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
Sponsor: LG Chem
Summary
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
Official title: A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children With Central Precocious Puberty
Key Details
Gender
All
Age Range
Any - 10 Years
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2026-08-01
Completion Date
2030-04-30
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
Leuprorelin
Leuprorelin will be administered every 4 weeks.